期刊文献+

肝细胞肝癌组织中Bcl-2核表达和SPARC表达临床意义的探讨 被引量:4

Relationship of Bcl-2 expression with SPARC expression in hepatocellular carcinoma,and their correlation with recurrence,metastasis,and prognosis
下载PDF
导出
摘要 目的探讨抗凋亡蛋白Bcl-2和富含半胱氨酸的酸性分泌蛋白(SPARC)在肝细胞肝癌中表达的关联性,及其与复发、转移和预后的关系。方法以石蜡包埋组织切片,免疫组织化学SP法染色检测126例肝细胞肝癌,分别在复发与转移组64例和非复发与转移组62例中分析Bcl-2核表达和SPARC的情况。结果复发与转移组Bcl-2核表达高于无复发与转移组(χ2=8.472,P=0.003),复发转移组SPARC表达高于无复发转移组(χ2=6.872,P=0.014),Bcl-2核表达阳性细胞率与SPARC阳性细胞率存在相关性。Bcl-2核表达组患者生存时间较短,差异具有显著性。结论 Bcl-2核表达阳性患者更易出现复发与转移,且与SPARC过度表达存在关联性,表明Bcl-2入核可能对肿瘤转移的相关生物学功能具有调节作用,可作为评价HCC复发、转移和不良生存预后的候选临床标志。 [ Objective ] To determine the correlation of the expression of the anti-apoptotic protein Bcl-2 with the expression of SPARC in human hepatocellular carcinoma, and their relationship with recurrence, metastasis, and prognosis. [Methods] Paraffin-embedded tissue sections of 126 hepatocellular carcinoma cases were subjected to SP immunohistochemical staining. The nuclear expression of Bcl-2 and SPARC were detected. A total of 64 cases had recurrence and metastasis, and the remaining 64 did not. [ Results ] The nuclear expression of Bcl-2 was higher in cases with recurrence band/or metastasis (χ2=8.472, P =0.003). Similarly, SPARC expression were higher in cases with recurrence and/or metastasis (χ2=6.872, P =0.014). The nuclear expression of Bcl-2 was correlated with the ex- pression of SPARC. Patients with positive nuclear expression of Bcl-2 had shorter survival time, and the difference was significant. [ Conclusions ] The nuclear expression of Bcl-2 was significantly correlated with metastasis and SPARC expression. Bcl-2 relocation into the nucleus may regulate metastasis-related proteins, which can be used as a clinical marker for evaluating recurrence, metastasis, and prognosis.
出处 《中国现代医学杂志》 CAS CSCD 北大核心 2013年第24期58-61,共4页 China Journal of Modern Medicine
关键词 BCL-2 SPARC 复发与转移 Bcl-2 SPARC recurrence and metastasis
  • 相关文献

参考文献2

二级参考文献33

  • 1Garcia M,Jemal A,Ward EM,et al.Global cancer facts & figures 2007.Atlanta (GA):American Cancer Society[OL].2007[2011-04-12].http://www.cancer.org/acs/groups/content/@nho/documents/document/globalfactsandfigures2007rev2p.pdf.
  • 2O'Dwyer P,Giantonio B,Levy D,et al.Gefitinib in advanced unresectable hepatocellular carcinoma:Results from the Eastern Cooperative Oncology Group's Study E1203[J].J Clin Oncol,2006,24(18s):4143.
  • 3Philip PA,Mahoney MR,Allmer C,et al.Phase Ⅱ study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer[J].J Clin Oncol,2005,23(27):6657-6663.
  • 4Thomas MB,Chadha R,Glover K,et al.Phase2 study oferlotinib in patients with unresectable hepatocellular carcinoma[J].Cancer,2007,110(5):1059-1067.
  • 5Thomas MB,Chadha R,Iwasaki M,et al.The combination of bevacizumab (B) and erlotinib (E) shows significant biological activity in patients with advanced hepatocellular carcinoma (HCC)[J].J Clin Oncol,2007,25(18s):4567.
  • 6Zhu AX,Stuart K,Blaszkowsky LS,et al.Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma[J].Cancer,2007,110(3):581-589.
  • 7Louafi S,Hebbar M,Rosmorduc O,et al.Gemcitabine,oxaliplatin (GEMOX) and cetuximab for treatment of hepatocellular carcinoma (HCC):Results of the phase Ⅱ study ERGO[J].J Clin Oncol,2007,25(18s):4594.
  • 8Ramanathan RK,Belani CP,Singh DA,et al.A phase Ⅱ study of lapatinib in patients with advanced biliary tree and hepatocellular cancer[J].Cancer Chemother Pharmacol,2009,64 (4):777-783.
  • 9Moon WS,Rhyu KH,Kang MJ,et al.Overexpression of VEGF and angiopoietin 2:a key to high vascularity of hepatocellular carcinoma[J].Modern Pathol,2003,16(6):552-557.
  • 10Schwartz JD,Schwartz M,Goldman J,et al.Bevacizumab in hepatocellular carcinoma in patients without metastasis and without invasion of the portal vein[J].J Clin Onool,2005,22 (14s):4088.

共引文献7

同被引文献58

  • 1YOUNESS ER, EL NEMR M, ORABY FS, et al. Evaluation of apoptotic marker Bcl2, CD4+, human hepatocyte growth factor and metalloproteinase-9 as tumor markers for patients with hep- atocellular carcinoma[J]. Indian J Clin Biochem, 2014, 29(3): 351-356.
  • 2XIANG J, XIANG Y, LIN S, et al. Antieancer effects of depro-teinized asparagus polysaccharide on hepatocellular carcinoma in vitro and in vivo[J]. Tumour Biol, 2014, 35(4): 3517-3524.
  • 3GONZALEZ-SANCHEZ E, MARIN J], PEREZ MJ. The expres- sion of genes involved in hepatocellular carcinoma chemoresis- tance is affected by mitoehondrial genome depletion[J]. Mol Pharm, 2014, 11(6): 1856-1868.
  • 4KAREV VE. Fas, FasL, and bcl-2 expression on hepatic in- tralobar lymphocytes in different variants of the natural course of chronic HBV and HCV infection and in its outcomes[J]. Arkh Patol, 2014, 76(1): 16-21.
  • 5HE XH, LIANG LH, DING J, et al. Advances in research on the role and mechanism of microRNAs in hepatic carcinogenesis [J]. Journal of Shanghai Jiaotong University (Medical Science), 2012, 32(9): 1264-1268.
  • 6WANG B, HSU SH, MAJUMDER S, et al. TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3[J]. Oncogene, 2010, 29(12): 1787-1797.
  • 7LEE CI-I, KIM J]4, LEE SW. The role of microRNAs in hep- atitis C virus replication and related liver diseases [J]. J Micro- biol, 2014, 52(6): 445-451.
  • 8L1U W, XU C, WAN H, et al. MicroRNA-106 overexpression promotes apoptosis, induces cell cycle arrest and inhibits the migration of human hepatoeellular carcinoma HepG2 cells[J]. Int J Mol Med, 2014, 34(2): 420-428.
  • 9Liu Y,Su Z,Li G,et al.Increased expression of metadherin protein predicts worse disease-free and overall survival in laryngeal squamous cell carcinoma[J].International Journal of Cancer,2013,133(3):671-679.
  • 10Siegel R,Naishadham D,Jemal A.Cancer statistics[J].CA Cancer J Clin,2012,62(1):1029.

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部